Lepu Biopharma Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Lepu Biopharma has a total shareholder equity of CN¥902.0M and total debt of CN¥729.6M, which brings its debt-to-equity ratio to 80.9%. Its total assets and total liabilities are CN¥2.4B and CN¥1.5B respectively.
Anahtar bilgiler
80.9%
Borç/özkaynak oranı
CN¥729.61m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | CN¥586.22m |
| Eşitlik | CN¥902.01m |
| Toplam yükümlülükler | CN¥1.54b |
| Toplam varlıklar | CN¥2.44b |
Son finansal sağlık güncellemeleri
Recent updates
Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt
Aug 23
The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%
Jul 18Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Jun 03Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%
Apr 15Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 2157's short term assets (CN¥744.1M) do not cover its short term liabilities (CN¥985.8M).
Uzun Vadeli Yükümlülükler: 2157's short term assets (CN¥744.1M) exceed its long term liabilities (CN¥553.2M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 2157's net debt to equity ratio (15.9%) is considered satisfactory.
Borcun Azaltılması: Insufficient data to determine if 2157's debt to equity ratio has reduced over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: 2157 has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: 2157 has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 19.3% each year.